Introduction
Lysophosphatidic acid (LPA) elicits diverse cellular responses such as cell proliferation, cell migration, cell survival and ion transport (Birgbauer and Chun, 2006) . Recent study has linked LPA/LPA receptors to the development of various cancers, in particular ovarian cancer (Fang et al., 2002) . LPA is present at elevated levels in the ascites of ovarian cancer patients (Xu et al., 1998) and produced by ovarian cancer cells but not normal ovarian epithelial cells (Eder et al., 2000) . LPA 2 and LPA 3 are overexpressed in most ovarian cancer cells (Wang et al., 2007b) . Laboratory investigation demonstrates that (1) LPA is capable of enhancing cell growth/ survival, cell motility and the production/activation of many proteases (Fishman et al., 2001; Do et al., 2007) ; (2) inducing the expression of pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and interleukin (IL)-8 (Hu et al., 2001; Schwartz et al., 2001) and (3) removing LPA by lipid phosphate phosphatase inhibits tumor development (Tanyi et al., 2003) . Taken together, these findings suggest that LPA may impact cancer progression through an autocrine system.
The levels of urokinase plasminogen activator (uPA) expression and activity are low in benign ovarian tumors but increased significantly in advanced ovarian tumors (Murthi et al., 2004) . High concentrations of uPA in the ascites/plasma correlate with the poor prognosis and response to chemotherapy (Schmalfeldt et al., 1995; Konecny et al., 2001) . Furthermore, uPA induces ovarian cancer cell proliferation and migration (Fischer et al., 1998; Kjoller and Hall, 2001 ) and inhibiting uPA function with specific inhibitors significantly decrease ovarian cancer invasion and metastasis (Suzuki et al., 2004) . Previous studies show that LPA induces uPA expression (Pustilnik et al., 1999 ) and we further demonstrate that inhibiting uPA expression blocks LPA-induced invasion . These findings strongly indicate that uPA may play a role in LPA-associated ovary oncogenesis.
Protein kinase C (PKC) belongs to a serine/threonine kinase family that include three classes of isoenzymesconventional, novel and atypical PKCs. Conventional PKCs (cPKCs) are dependent on calcium and diacylglycerol (DAG) for their activity, whereas novel PKCs (nPKCs) are calcium-independent and atypical PKCs (aPKCs) are both calcium-and DAG-independent (Corbalan-Garcia and Gomez-Fernandez, 2006) . Despite their functional specificity, all three classes can activate nuclear factor (NF)-kB. For instance, PKCb and PKCy mediate B-and T-cell antigen receptorinduced NF-kB activation, respectively (Matsumoto et al., 2005; Sommer et al., 2005) . PKCz is required for IL-1-induced NF-kB activation in articular chondrocytes (LaVallie et al., 2006) . Several recent studies have identified key signaling molecules downstream of PKCs to mediated T-and B-cell antigen receptormediated NF-kB activation: (1) CARMA1, a scaffolding protein which serves to integrate the upstream signal of PKCs with downstream effectors (Wang et al., 2002) ; (2) Bcl10, an intermediate bridging protein (Willis et al., 1999) and (3) MALT1, an effector which can stimulate I-Kappa B kinase (IkB kinase) through interaction with Bcl10 . Although CARMA1 expression is restricted to hematopoietic cells, CARMA3, Bcl10 and MALT1 are present in almost all tissue/cells. It is of interest to determine whether CARMA1/3-Bcl10-MALT1 signaling complex can facilitate PKC-mediated NF-kB activation in ovarian cancer cells.
LPA was reported to upregulate uPA expression in human ovarian cancer cells but not in normal ovarian epithelial cells (Pustilnik et al., 1999) . We further showed that a G i -Ras-NF-kB-dependent signaling pathway mediates LPA-induced uPA upregulation in ovarian cancer cells . However, it is unknown what signaling components link Ras to NF-kB for this LPAinduced event. Using specific inhibitors and dominantnegative PKC mutants, we found that PKCa is necessary for LPA-induced NF-kB activation and uPA upregulation. To reveal the functional link between Ras and PKCa, we found that LPA stimulation led to PKCa activation, but this activation was abrogated by dominant-negative Ras mutant and Ras inhibitor farnesyltransferase inhibitor (FTI-277). Furthermore, LPA induced Ras and PKCa interaction and this interaction was sensitive to the inhibitors of both farnesyltransferase and cPKC. These results indicate that PKCa is a signaling component downstream of Ras mediating LPA-induced cellular event.
In this study, we also investigated the role of newly characterized signaling complex CARMA3-Bcl10-MALT1 in LPA-induced NF-kB activation/uPA upregulation. Forced expression of dominant-negative CARMA3 mutant or treatment of cells with siRNAs specifically targeting CARMA3, Bcl10 or MALT1 abrogated these LPA-induced events, implicating the importance of CARMA3-Bcl10-MALT1 in LPA-associated signaling in ovarian cancer cells. Finally, we provide evidence that PKCa-CARMA3 signaling axis plays an essential role in LPA-induced ovarian cancer cell in vitro invasion.
Results
PKC inhibitor inhibits LPA-induced NF-kB activation/ uPA upregulation in ovarian cancer cells We previously show that Ras works downstream of G i to mediate LPA-induced NF-kB activation and uPA upregulation . As PKCs can be activated by Ras (Dlugosz et al., 1994; Perletti et al., 1996; Pal et al., 2001) and PKCs are involved in LPA-induced NFkB activation in bronchial epithelial cells (Cummings et al., 2004) , we examined whether PKC activity is needed for LPA-induced NF-kB activation and uPA upregulation in ovarian cancer cells. Ovarian cancer OVCAR3 and SK-OV3 cells were treated with calphostin C, bisindolylmaleimide I or Go¨6097 for 2 h and then stimulated with 10 mM LPA. LPA gave rise two-to threefold increase in NF-kB promoter activity and five-to eightfold increase in the level of uPA protein over the unstimulated cells (Figures 1a and b) . Pretreatment of cells with pan-PKC inhibitor calphostin C and bisindolylmaleimide abolished LPA-induced NF-kB activation and LPA upregulation (Figures 1a and b) . Interestingly, Go¨6097, an inhibitor of cPKC, inhibited these LPAinduced events equally well as the pan-PKC inhibitors (Figures 1a and b) . To determine the specificity of these inhibitors in LPA-associated action, we examined how these inhibitors affected tumor necrosis factor-a (TNFa)-induced events. TNFa significantly increased both NFkB promoter activity and uPA level (Supplementary Figures S1A and B) . In contrary to LPA-induced events, TNFa-induced events were not sensitive to these inhibitors (Supplementary Figures S1A and B) . These results suggest that cPKC activity is specifically required for LPA-induced NF-kB activation and uPA upregulation.
PKCa mediates LPA-induced NF-kB activation/uPA upregulation To identify the PKC isoform involved in LPA action, we first examined the presence of PKC isoforms by immunoblotting with subtype-specific antibodies and found that PKCa was the only cPKC member in SK-OV3 and OVCAR3 lines (Supplementary Figure S2A) . In addition, PKCy (an nPKC) and PKCz (an aPKC) were also seen (Supplementary Figure S2A) . In subsequent experiments, cells were transfected with NF-kB promoter reporter gene construct and then infected with Ad containing dominant-negative PKCa, y or z. After serum starvation, cells were stimulated with LPA for 4 h. While the overexpression of all three dominant-negative PKC mutants was readily seen (Figure 2b ), only dominant-negative PKCa attenuated LPA-induced NF-kB activation ( Figure 2a ). In parallel, we expressed the same PKC mutants in these cells and subsequently determined how their expression affected uPA upregulation. Dominant-negative PKCa, but not dominantnegative PKCy or PKCz, diminished LPA-induced uPA upregulation in both lines ( Figure 2b ). As overexpression of dominant-negative PKCa did not inhibit TNFa-induced NF-kB activation and uPA upregulation (Supplementary Figures S3A and B) , these results suggest that PKCa specifically mediates these LPAinduced events in ovarian cancer cells.
LPA activates PKCa in a Ras-dependent manner
Our previous studies demonstrate the importance of Ras in LPA-induced uPA upregulation .
Others also show the ability of Ras to activate PKC (Dlugosz et al., 1994; Perletti et al., 1996; Pal et al., 2001) . We hypothesized that PKCa might act downstream of Ras to facilitate LPA action. To test this hypothesis, we first determined the effect of LPA on PKCa activation in SK-OV3 and OVCAR3 lines. Overnight-starved cells were stimulated with 10 mM LPA for various times and then harvested for immunoblotting. As PKCa activation accompanies with serine657 phosphorylation, we determined PKCa activation by immunoblotting with anti-phosphoPKCa(Ser657) antibody. The serine657 phosphorylation of PKCa was low in unstimulated cells, but increased significantly and peaked between 30 and 60 min (Figure 3a ). These results demonstrate the ability of LPA to activate PKCa.
We next examined the potential involvement of Ras in LPA-induced PKCa activation. Cells were infected with Ad containing dominant-negative H-Ras followed by 1-hr LPA stimulation. LPA induced PKCa activation in cells infected with control Ad (Figure 3b ), but this induction was reduced in cells expressing dominantnegative H-Ras ( Figure 3b ). As Ras activation requires farnesylation, we examined how blocking Ras activity with farnesyltransferase inhibitor would affect LPAinduced PKCa activation. Cells were treated with farnesyltransferase inhibitor (FTI-277) or geranylgeranyltransferase inhibitor (GGTI-298) for 2 h prior to LPA-stimulation. FTI-277, but not GGTI-298, abrogated PKCa activation (Figure 3c ). These results suggest that LPA induces PKCa activation in a Ras-dependent manner.
LPA stimulation facilitates PKCa-Ras interaction As PKCa action leads to PKCa translocation to the plasma membrane and active Ras is known to locate on the plasma membrane, we hypothesized that LPA stimulation may lead both Ras and PKCa in the close proximity thus allowing Ras to activate PKCa. To test this hypothesis, SK-OV3 cells were stimulated with LPA for 10 min, then lysed for immunoprecipitation with PKCa mAb. Immunoblotting with the immunoprecipitates showed that little Ras was detected in PKCa immunoprecipitate of the unstimulated cells while significantly more Ras observed in LPA-stimulated cells (Figure 4 ). FTI-277 or Go¨6976 treatment prevented Ras-PKCa interaction in LPA-stimulated cells as indicated by significant less Ras detected in PKCa immunoprecipitates (Figure 4) . These results suggest that (1) LPA stimulation leads to Ras-PKCa interaction and (2) the activities of Ras and PKCa are necessary for their interaction.
CARMA3-Bcl10-MALT1 signaling cascade is required for LPA-induced uPA upregulation in ovarian cancer cells CARMA1/3-Bcl10-MALT1 play an essential role in PKC-mediated NF-kB activation (Wang et al., 2002 (Wang et al., , 2007a Klemm et al., 2007) . A recent study further shows that CARMA3 is important for LPA-induced PKCa-CARMA3 in LPA-induced uPA upregulation C Mahanivong et al NF-kB activation in murine embryonic fibroblasts (Grabiner et al., 2007) . To investigate whether such signaling complex was involved in LPA-induced uPA upregulation in ovarian cancer cells, we first performed immunoblotting with specific CARMA antibodies and detected only CARMA3 in OVCAR3 and SK-OV3 cells (data not shown). To address the role of CARMA3, we chose a dominant-negative CARMA3 mutant for our studies. This mutant, CARMA3DCARD, contains a deletion of CARD, a protein-protein interaction domain that recruits the downstream signaling protein, Bcl10, through CARD-CARD interaction and thus interrupting signal transmission from PKC to Bcl10/ MALT1 . Expression of this CARMA3 mutant inhibited LPA-induced NF-kB activation and uPA upregulation in both SK-OV3 and OVCAR3 cells (Figure 5a ), while it displayed no effect on TNFa-induced events (Supplementary Figure S4A) . Meanwhile, we also designed three CARMA3 siRNAs (see Supplementary Material) and introduced them into SK-OV3 and OVCAR3 cells. Two siRNAs that silenced CARMA3 expression inhibited LPA-induced (but not TNFa-induced) events (Figure 5b and Supplementary Figure S4B ), while the siRNA that did not alter CARMA3 expression displayed no effect (Figure 5b) . These results thus demonstrate the importance and specificity of CARMA3 in LPA-induced uPA upregulation in ovarian cancer cells.
We next examined the requirement of Bcl10 and MALT1 in LPA action by silencing their expression with siRNAs in SK-OV3 cells. Similar to CARMA3 siRNAs, siRNAs that diminished Bcl10 (siRNA-1) or MALT1 (all three siRNAs) expression inhibited LPAinduced (but not TNFa-induced) events (Figures 5c and  d ; Supplementary Figures S4C and D) . Our studies clearly demonstrate the essential role of CARMA3-Bcl10-MALT1 signaling complex in LPA-induced uPA upregulation in ovarian cancer cells.
PKCa-CARMA3 signaling cascade is essential for LPA-stimulated in vitro cell invasion As uPA is important for LPA-induced invasion , we investigated whether PKCa-CARMA3 signaling axis was similarly important for LPA-induced invasion. SK-OV3 cells were infected with Ad containing dominant-negative PKCa, CARMA3 (CARMA3D CARD) or non-phosphorylable IkB (Ikm) and then analysed for LPA or TNFa-stimulated in vitro invasion. Both LPA and TNFa induced significant invasion in cells infected with control Ad (Figure 6 ). Dominantnegative PKCa, CARMA3DCARD and Ikm all inhibited LPA-induced invasion (Figure 6a ). However, only the expression of Ikm inhibited TNFa-induced invasion (Figure 6b ). These results suggest that PKCa-CARMA3 axis is essential for LPA-induced (but not TNFainduced) ovarian cancer cell invasion although NF-kB activity is required for both.
Discussion
An early study reported that LPA significantly induced uPA expression in ovarian cancer cells but not in normal ovary epithelial cells (Pustilnik et al., 1999) , we further found that a signaling pathway consisting G i -Ras-NFkB mediated this LPA-induced event . However, it was unknown how signal was transmitted from Ras to NF-kB. Using specific PKC inhibitors and dominant-negative PKC mutants, we found that Go¨6876 (a cPKC inhibitor) and dominant-negative Figure 2 Protein kinase C (PKC)a is involved in lysophosphatidic acid (LPA)-induced nuclear factor (NF)-kB activation/urokinase plasminogen activator (uPA) upregulation. (a) pNF-kB-luc-transfected SK-OV3 and OVCAR3 cells were infected with control Ad or Ad containing dominant-negative PKCa, PKCy or PKCz for 24 h followed by overnight starvation. Cells were stimulated with 10 mM LPA for 4 h and then assayed for NF-kB promoter activity. (b) Cells were infected with control Ad or Ad containing dominantnegative PKCa, PKCy or PKCz for 24 h followed by overnight starvation. Cells were stimulated with 10 mM LPA for 16 h and then subjected to immunoblotting to detect uPA and actin with the respective antibodies.
PKCa-CARMA3 in LPA-induced uPA upregulation C Mahanivong et al PKCa diminished both LPA and Ras-induced NF-kB activation/uPA upregulation (Figure 1 and Supplementary Figure S5 ). Although PKC isoforms from all three classes can activate NF-kB and upregulate uPA (Supplementary Figure S2) , only dominant-negative PKCa blocked these LPA-induced events (Figure 2 ). These findings suggest that PKCa is specifically involved in LPA-induced NF-kB activation/uPA upregulation in ovarian cancer cells. A recent study reported that PKCd mediates LPA-induced NF-kB activation/IL-8 secretion in bronchial epithelial cells (Cummings et al., 2004) . However, the results from our experiments ruled out the role of PKCd in LPA-induced events in ovarian cancer cells (Supplementary Figure S6) . It is likely that a particular PKC isoform may mediated LPA-induced NF-kB activation in a particular cell type. Ras activates PKCa in primary keratinocytes and PKCa activity is required for Ras-induced keratin K1 and K10 expression (Dlugosz et al., 1994) . PKCe is activated by Ras and promotes Ras-mediated transformation of rat colon epithelial cells (Perletti et al., 1996) . In fibrosarcoma HT1080 cells, Ras associates with and phosphorylates PKCz and PKCz is essential for Rasmediated VEGF expression (Pal et al., 2001) . We showed that LPA activated PKCa (Figure 3 ) and induced Ras-PKCa interaction (Figure 4) . Blocking Ras activity abolished PKCa activation (Figure 3 ) and Ras-PKCa interaction (Figure 4) . In fact, ovarian cancer cells expressing active Ras displayed elevated PKCa activity and this elevated activity was diminished by Ras inhibitor FTI-277 (Supplementary Figure S5) . Our observation thus provides another example of functional link between Ras and PKC.
CARMA1, Bcl10 and MALT1 function as part of a signaling complex to bridge PKC to IKKs, thus facilitating NF-kB activation in lymphocytes (Matsumoto et al., 2005; Sommer et al., 2005) . In our study, we found that intercepting CARMA3 function with a CARD-deleted CARMA3 or silencing CARMA3 expression with specific siRNAs attenuated LPA-induced NF-kB activation and uPA upregulation ( Figure 5) . Moreover, knocking down Bcl10 or MALT1 also inhibited these LPA-induced events ( Figure 5 ). These findings suggest a general role of CARMA1/3-Bcl10-MALT1 in NF-kB activation. Our conclusions are supported by recent studies that reported defective Figure 3 Lysophosphatidic acid (LPA) activates protein kinase C (PKC)a in a Ras-dependent manner. (a) Overnight-starved SK-OV-3 or OVCAR3 cells were stimulated with 10 mM LPA for various times, then lysed and lysates subjected to immunoblotting to detect phosphor-PKCa(Ser657) and PKCa with the respective antibodies. (b) Cells were infected with control Ad or Ad containing dominantnegative Ras for 24 h followed by overnight starvation. Cells were stimulated with 10 mM LPA for 1 hr and then subjected to immunoblotting to detect phosphor-PKCa(Ser657) and PKCa with the respective antibodies. (c) Overnight-starved cells were treated with 1 mM FTI-277 or GGTI-298 for 2 h and then stimulated with 10 mM LPA for 1 hr followed by immunoblotting to detect phosphoPKCa(Ser657) and PKCa with the respective antibodies. PKCa-CARMA3 in LPA-induced uPA upregulation C Mahanivong et al NF-kB activation in CARMA3, Bcl10 or MALT1-defective murine embryonic fibroblasts by LPA (Grabiner et al., 2007; Klemm et al., 2007; Wang et al., 2007a) .
In conclusion, we have characterized PKCa-CAR-MA3 axis as part of a signaling pathway mediating LPA-induced uPA upregulation in ovarian cancer cells. As uPA plays a critical role in ovary neoplasias, we speculate that PKCa or CARMA3 may represent attractive therapeutic targets for ovary malignancies.
Materials and methods

Immunoblotting
To determine the effect of PKC inhibitors, overnight-starved OVCAR3 and SK-OV3 cells were treated with calphostin C (0.1 and 0.5 mM), bisindolylmaleimide I (2 and 10 mM) or Go¨6097 (1 and 5 mM) for 2 h prior to 16-hr 10 mM LPA stimulation. Cells were lysed and lysates analysed by immunoblotting to detect uPA. To determine the effect of dominantnegative mutants of signaling components, cells were infected with 10 3 viral particles per cell control Ad or Ad encoding CARMA3DCARD, dominant-negative PKCa, PKCy or PKCz for 24 h, serum-starved for 24 h and then stimulated with 10 mM LPA for 16 h followed by immunoblotting to detect uPA expression. To determine the effect of CARMA3, Bcl10 and MALT1 siRNAs, cells were transfected with 100 nM CARMA3, Bcl10 or MALT1 siRNAs using Lipofectamine 2000 for 48 h and then serum-starved for another 24 h. Cells were stimulated with 10 mM LPA for 16 h followed by immunoblotting to detect uPA.
To determine PKCa activity, overnight-starved cells were stimulated with 10 mM LPA for varying times, then lysed and (a) pNF-kB-luc-transfected SK-OV3 or OVCAR3 cells were infected with control Ad or Ad containing CARD-deleted CARMA3 (Ad.CARMA3(À)) for 24 h followed by overnight starvation. Cells were stimulated with 10 mM LPA for 4 or 16 h followed by the analyses of NF-kB promoter activity and uPA expression as described in the 'Materials and methods' section. (b-d) SK-OV3 cells were transfected with 100 nM control, CARMA3, Bcl10 or MALT1 siRNAs for 2 days. Part of the cells was transfected with pNF-kB-luc for analysing LPA-induced NF-kB promoter activation as described in the 'Materials and methods' section. Remaining cells were analysed for LPA-induced uPA expression as described in the 'Materials and methods' section.
PKCa-CARMA3 in LPA-induced uPA upregulation C Mahanivong et al lysates subjected to immunoblotting to detect phosphoPKCa(Ser657) and PKCa. To determine the effect of dominant-negative Ras mutant, cells were infected with control Ad or Ad containing H-Ras(N17) at 10 3 viral particles per cell for 24 h and then starved for another 24 h. Cells were stimulated with 10 mM LPA for 60 min and then analysed for phospho-PKCa(Ser657). To determine the effect of FTI-277 and GGTI-298, overnight-starved cells were treated 1 mM FTI-277 or 1 mM GGTI-298 for 2 h and then stimulated 10 mM LPA for 60 min followed by immunoblotting to detect phosphoPKCa(Ser657).
Analysis of NF-kB activity SK-OV3 or OVCAR3 cells were transfected with pNF-kB-Luc plasmid (Stratagene, San Diego, CA, USA) and pAc-RLuc (Promega, Madison, WI, USA) at 30:1 ratio for 24 h using Lipofectamine2000. To determine the effect of PKC inhibitors, transfected cells were starved for 24 h and then treated with calphostin C (0.1 and 0.5 mM), bisindolylmaleimide I (2 and 10 mM) or Gö 6097 (1 and 5 mM) for 2 h followed by 4-hr stimulation of 10 mM LPA. Cells were lysed and lysates measured for luciferase activities using Dual-luciferase Reporter Assay System (Promega). To determine the effect of dominant-negative forms of CARMA3, PKCa, y and z, transfected cells were infected with control Ad or Ad encoding CARMA3DCARD, dominant-negative PKCa, y or z (10 3 viral particles per cell) for 24 h, and then starved for 24 h followed by 4-hr LPA stimulation. To determine the effect of CARMA3, Bcl10 and MALT1 siRNAs, cells were first transfected with 100 nM CARMA3, Bcl10 or MALT1 siRNAs for 48 h and then again transfected with pNF-kB-Luc/pAcRluc for 24 h. Cells were then starved for 24 h followed by 4-hr LPA stimulation. The Renilla luciferase activity was used to normalize NF-kB promoter activity.
Immunoprecipitation
Overnight-starved SK-OV3 cells were treated with 1 mM FTI-277 or 5 mM Go¨6976 for 2 h or left untreated, and then stimulated with 10 mM LPA for 10 min. Cells were lysed, lysates immunoprecipitated with PKCa mAb and immunoprecipitates subjected to immunoblotting with anti-Ras polyclonal antibody. Figure 6 Intercepting PKCa-CARMA3 axis inhibits SK-OV3 in vitro invasion. SK-OV3 cells were infected with control Ad or Ad containing dominant-negative PKCa, CARMA3DCARD or Ikm, and then added into matrigel invasion chambers to analyse in vitro invasion as described in Supplementary Material. Lysophosphatidic acid (LPA, 10 mM) (a) or TNFa (50 ng ml À1 ) (b) was added in the underwells to stimulate cell invasion.
